These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35443000)

  • 1. Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
    Escobar Cervantes C; Martí-Almor J; Cabeza AIP; Bowrin K; Llorac Moix A; Genís Gironès M; Gasche D; Millier A; Tardu J; Toumi M; Briere JB
    PLoS One; 2022; 17(4):e0266658. PubMed ID: 35443000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
    Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
    Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
    Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
    PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
    Liu CY; Chen HC
    Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
    Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
    Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.
    Deitelzweig S; Bergrath E; di Fusco M; Kang A; Savone M; Cappelleri JC; Russ C; Betts M; Cichewicz A; Schaible K; Tarpey J; Fahrbach K
    Future Cardiol; 2022 May; 18(5):393-405. PubMed ID: 35360925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
    Zhou H; Nie X; Jiang M; Dong W
    J Clin Pharm Ther; 2022 Apr; 47(4):523-530. PubMed ID: 34783090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
    de Jong LA; Groeneveld J; Stevanovic J; Rila H; Tieleman RG; Huisman MV; Postma MJ; van Hulst M
    PLoS One; 2019; 14(9):e0222658. PubMed ID: 31527894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
    Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
    Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
    Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
    Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.